Skip to main content
. 2013 Dec 3;4:2883. doi: 10.1038/ncomms3883

Figure 7. Reversal of hepatic steatosis by the reduction of SREBP-1 levels.

Figure 7

(a) Western blotting analysis of SREBP-1 and ABCA1 levels in the livers of miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice. Representative western blot images are shown (n=4). (b) Serial changes in BW levels of miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice fed HFD under pair-feeding condition (n=12 each). (c) Serial changes in glucose levels after intraperitoneal injection of glucose into miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice (n=11–12 each). *P<0.05 and **P<0.01 versus miR-33−/−Srebf1+/− mice. #P<0.05, ##P<0.01 and ###P<0.001 versus miR-33+/+Srebf1+/+ mice in one-way analysis of valiance test. (d) AUC of glucose levels in glucose tolerance tests in miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice (n=11–12 each). **P<0.01 versus miR-33−/−Srebf1+/− mice in one-way analysis of valiance test. (e) Representative microscopic images of the liver of miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice fed HFD. Scale bars, 200 μm. (f) Cholesterol and triglyceride levels in the liver of miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice fed HFD. *P<0.05 and **P<0.01 in one-way analysis of valiance test. (g) Representative microscopic images of the adipose tissue of miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice fed HFD. Scale bars, 200 μm. (h) Serum leptin levels of miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ and miR-33−/− Srebf1+/− mice fed HFD. *P<0.05, **P<0.01 and ***P<0.001 in one-way analysis of valiance test. Values are the means±s.e.m.